Department of Psychology, University of Calgary, Calgary, AB T2N 1N4, Canada.
Division of Psychosocial Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.
Curr Oncol. 2021 Jul 5;28(4):2496-2515. doi: 10.3390/curroncol28040227.
Adjuvant endocrine therapy (AET) is recommended after hormone receptor-positive breast cancer to reduce risk of recurrence, but adherence is sub-optimal in many women. Behavioral interventions have been ineffective in improving adherence rates to AET. This qualitative descriptive study investigates factors that support women in AET use and suggestions for interventions to improve AET use and management. Interviews with women who persisted with AET ( = 23), women who discontinued AET ( = 15), and healthcare providers (HCPs; oncologists, oncology residents, and pharmacists; = 9) were conducted, transcribed, and described using thematic analysis. Data collection stopped once saturation occurred (i.e., no new codes or themes emerged during interviews). Two researchers created codes and developed themes in an iterative process; a third researcher verified the representativeness of final themes. This study was approved by the Health Research Ethics Board of Alberta (ID: HREBA.CC-17-0513). Women who persisted described being prepared for side effects and having self-management strategies, strong rationale for AET use, supportive HCPs, and available resources as relevant factors. Women who discontinued described feeling overwhelmed by side effects, information needs, drawbacks of AET, helpful/unhelpful experiences with HCPs, and contextual factors as relevant to their discontinuation. HCPs described health system-related and patient-related barriers, side effect management, and patient-provider interactions as relevant to supporting AET use. The considerable overlap in themes among the three groups suggests broad recognition of salient factors relevant to AET use and that associated strategies to improve use may be acceptable to patients and providers alike. Factors supporting AET use could include the following: education (which may be necessary but insufficient), developing a strong personal rationale for use, being prepared for side effects, having side effect management strategies, reciprocal communication between patients and HCPs, and accessible resources.
辅助内分泌治疗(AET)被推荐用于激素受体阳性乳腺癌患者,以降低复发风险,但许多女性的依从性并不理想。行为干预措施在提高 AET 依从率方面效果不佳。这项定性描述性研究调查了支持女性使用 AET 的因素,并提出了改善 AET 使用和管理的干预措施建议。对坚持使用 AET 的女性(n=23)、停止使用 AET 的女性(n=15)和医疗保健提供者(包括肿瘤学家、肿瘤学住院医师和药剂师;n=9)进行了访谈,转录并使用主题分析进行了描述。一旦达到饱和(即访谈中没有出现新的代码或主题),就停止数据收集。两位研究人员在迭代过程中创建了代码并开发了主题;第三位研究人员验证了最终主题的代表性。本研究得到了阿尔伯塔省健康研究伦理委员会的批准(ID:HREBA.CC-17-0513)。坚持使用 AET 的女性描述了对副作用有准备、有自我管理策略、有强烈的 AET 使用理由、有支持性的医疗保健提供者和可用资源等相关因素。停止使用 AET 的女性则描述了因副作用、信息需求、AET 的缺点、与医疗保健提供者的有益/无益经历以及环境因素而感到不知所措。医疗保健提供者描述了与健康系统相关的和与患者相关的障碍、副作用管理以及患者与提供者之间的互动等与支持 AET 使用相关的因素。这三个群体之间主题的大量重叠表明,人们广泛认识到与 AET 使用相关的重要因素,并且与提高使用相关的策略可能会被患者和提供者所接受。支持 AET 使用的因素可能包括以下内容:教育(这可能是必要的,但还不够)、为使用制定强有力的个人理由、对副作用有准备、有副作用管理策略、患者与医疗保健提供者之间的互惠沟通,以及可获得的资源。